Company intelligence / Profile preview

Dr Cha

Seongnam, Gyeonggi-do, South Koreafifthaveplasticsurgery.com ↗

Ownership: Private
Employees: ~292
Development stage: Commercial

Overview

CHA Biotech has advanced several programs into clinical trials. Notably, it received Korea’s first Phase I/IIa IND approval for CordSTEM in stroke and has completed global Phase II studies for PLX-PAD in intermittent claudication. Other programs include early-stage trials for Alzheimer’s disease and degenerative conditions using stem cell-based therapies

Therapeutic areas: OncologyNeurology
Modalities: Cell therapyStem cell therapyNatural killer cell therapyGene therapy
Industry: Biotech

Partnerships

Astellas Pharma (“Stem Cell & Regenerative Medicine International” joint venture)

Beyond the preview

Go deeper on Dr Cha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr Cha.

Explore the full profile